FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 301–400 of 1,002
Murthy, D., Attri, K. S., Suresh, V., Rajacharya, G. H., Valenzuela, C. A., Thakur, R. K., Zhao, J., Shukla, S. K., Chaika, N. V., LaBreck, D. A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315509121 · Cited by 45
“Our study demonstrated that pharmacological inhibition of SAT1 using pentamidine synergistically enhanced the antitumor effects of FOLFIRINOX, the current standard - of - care therapy for PDAC (40), in an orthotopic mouse model of PDAC.”
BackgroundCurrent Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 48
Hank, T. P., Sandini, M., Qadan, M., Weniger, M., Ciprani, D., Li, A., Ferrone, C. R., Warshaw, A. L., Lillemoe, K. D., & Castillo, C. F. F.-D. (2019) · Pancreatology · doi:10.1016/j.pan.2019.10.007 · Cited by 52
Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R. B., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3034 · Cited by 45
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson, J., Ramaswamy, Y., Singh, G., Gorfe, A. A., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2020) · Cancers · doi:10.3390/cancers12051341 · Cited by 45
“[7] demonstrated an improved OS rate at 3 years of 63.”
BackgroundNano drug delivery systems in upper gastrointestinal cancer therapy
Salapa, J., Bushman, A., Lowe, K., & Irudayaraj, J. (2020) · Nano Convergence · doi:10.1186/s40580-020-00247-2 · Cited by 48
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 51
Quercetin improves pancreatic cancer chemo‐sensitivity by regulating oxidative‐inflammatory networks
Hu, Y., Li, R., Jin, J., Wang, Y., & Ma, R. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14453 · Cited by 46
Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
Raufi, A. G., May, M. S., Hadfield, M. J., Seyhan, A. A., & El‐Deiry, W. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044238 · Cited by 50
“8 months) [3,5] whereas the addition of nab-paclitaxel to gemcitabine improves median overall survival by 1.”
BackgroundYang, Z., Xu, C., Lee, J. X., & Lum, G. Z. (2024) · Advanced Materials · doi:10.1002/adma.202408750 · Cited by 54
Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer
Ghidini, M., Lampis, A., Mirchev, M. B., Okuducu, A. F., Ratti, M., Valeri, N., & Hahne, J. C. (2020) · Genes · doi:10.3390/genes12010033 · Cited by 50
Miller, J. A., Toesca, D. A. S., Baclay, J. R. M., Vitzthum, L. K., Dubrowski, P., Pollom, E. L., & Chang, D. T. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.07.1698 · Cited by 45
Chen, J., Qiu, M., Zhang, S., Li, B., Li, D., Huang, X., Qian, Z., Zhao, J., Wang, Z., & Tang, D. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.07.080 · Cited by 42
Daamen, L. A., Dorland, G. A., Brada, L. J. H., Groot, V. P., van Oosten, A. F., Besselink, M. G., Bosscha, K. P., Bonsing, B. A., Busch, O. R., Cirkel, G. A., et al. (2021) · HPB · doi:10.1016/j.hpb.2021.09.004 · Cited by 45
Usón, P. L. S., Silva, D. D. E., de Castro, N. M., Victor, E. D. S., Rother, E. T., Araújo, S. E. A., Borad, M. J., & Moura, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100771 · Cited by 57
“About 10%-20% of the patients with pancreatic cancer are diagnosed in earlier stages; in this group of patients, options including chemotherapy, radiotherapy and surgery can improve outcomes and even result in cures.(3,4) Lately, the best strategy to treat resectable pancreatic cancer (RPC) has been an area of debate.”
BackgroundMethodInfluentialAslakson, R. A., Rickerson, E. M., Fahy, B. N., Waterman, B. L., Siden, R., Colborn, K. L., Smith, S., Verano, M., Lira, I., Hollahan, C. G., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14660 · Cited by 48
Hall, W. A., & Goodman, K. A. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1277-1 · Cited by 44
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
Mizrahi, J. D., Rogers, J. E., Hess, K. R., Wolff, R. A., Varadhachary, G. R., Javle, M. M., Shroff, R. T., Ho, L., Fogelman, D. R., Raghav, K. P. S., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.005 · Cited by 43
Cellini, F., ARCELLI, A., Simoni, N., Caravatta, L., Buwenge, M., Calabrese, A., Brunetti, O., Genovesi, D., Mazzarotto, R., Deodato, F., et al. (2020) · Cancers · doi:10.3390/cancers12071729 · Cited by 47
“Therefore, further studies are justified in this field, which combine advanced RT techniques with the standard CT regimen in the adjuvant setting (FOLFIRINOX), as defined by the “PRODIGE” Group’s study [53].”
MethodImmediate and Long-Term Outcomes of Reperfusion Therapy in Patients With Cancer
Yoo, J., Kim, Y. D., Park, H., Kim, B. M., Bang, O. Y., Kim, H. C., Han, E., Kim, D. J., Heo, J., Kim, M.-Y., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.032380 · Cited by 46
Ultrasound‐Responsive Microfluidic Microbubbles for Combination Tumor Treatment
Huang, D., Zhang, X., Zhao, C., Fu, X., Zhang, W., Kong, W., Zhang, B., & Zhao, Y. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100050 · Cited by 46
Mas, L., Lupinacci, R. M., Cros, J. F., Bachet, J., Coulet, F., & Svrcek, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136756 · Cited by 47
“There is only limited evidence of the beneficial effect of adjuvant therapy in resected IPMC and this is mostly derived from the results of phase III clinical trials using pooled data of cPDAC and IPMC [100,101].”
MethodSelf-citationPausch, T. M., Liu, X., Cui, J., Wei, J., Miao, Y., Heger, U., Probst, P., Heap, S., & Hackert, T. (2021) · Cancers · doi:10.3390/cancers14010057 · Cited by 46
“For instance, 5-year survival for patients receiving curative treatment has increased by an order of magnitude since the early 2000s [10,11].”
BackgroundSesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer
Laurella, L. C., Mirakian, N. T., Garcia, M. N., Grasso, D., Sülsen, V. P., & Papademetrio, D. L. (2022) · Molecules · doi:10.3390/molecules27113492 · Cited by 43
“A cocktail of drugs, composed of 5-fluorouracil, leucovorin, oxaliplatin and irinotecan, termed modified FOLFIRINOX and the nab-paclitaxel plus gemcitabine are the most extended chemotherapeutic options, though they have very poor performance with highly toxic effects [22].”
BackgroundKiemen, A. L., Damanakis, A. I., Braxton, A. M., He, J. P., Laheru, D. A., Fishman, E. K., Chames, P., Almagro-Pérez, C., Wu, P., Wirtz, D., et al. (2023) · Med · doi:10.1016/j.medj.2022.11.009 · Cited by 52
Precision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 47
Kim, E. J., Kim, Y. J., Lee, H. I., Jeong, S. H., Nam, H. J., & Cho, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134646 · Cited by 44
Bouchart, C., Navez, J., Closset, J., Hendlisz, A., Gestel, D. V., Moretti, L., & Laethem, J. V. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936093 · Cited by 44
Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Franck, C., Müller, C., Rosania, R., Croner, R. S., Pech, M., & Venerito, M. (2020) · Cancers · doi:10.3390/cancers12071955 · Cited by 45
“Table 2 shows dosages and side effects of the different FOLFIRINOX formulations investigated in phase III trials [19,23].”
BackgroundGupta, N., & Yelamanchi, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3158 · Cited by 58
Du, J., Lu, C., Mao, L., Zhu, Y., Kong, W., Shen, S., Tang, M., Bao, S., Cheng, H., Li, G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100972 · Cited by 46
“Several clinical trials have demonstrated that adjuvant therapy can prolong the survival of patients after resection.(5,6) Meanwhile, R0 resection still appears relevant prognostic after pretreatment, and various studies encourage neoadjuvant and induction therapy that may increase the R0 resection rate and further im…”
BackgroundAssociation Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Fistula
Ellis, R. J., Brajcich, B. C., Bertens, K. A., Chan, C. H. F., Castillo, C. F. F.-D., Karanicolas, P. J., Maithel, S. K., Reames, B. N., Weber, S. M., Vidrí, R. J., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005955 · Cited by 41
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Brozos-Vázquez, E., Toledano‐Fonseca, M., Costa‐Fraga, N., García‐Ortiz, M. V., Díaz‐Lagares, Á., Rodríguez‐Ariza, A., Aranda, E., & López‐López, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102719 · Cited by 59
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Clinical Trial
Cecchini, M., Salem, R. R., Robert, M. E., Czerniak, S., Bláha, O., Zelterman, D. A., Rajaei, M., Townsend, J. P., Cai, G., Chowdhury, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1575 · Cited by 53
Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 143
“191,192 195 A systematic review of 11,713 patients who received treatment with preoperative therapy reported resection rates of 61% in borderline resectable PDAC and 22% in locally advanced PDAC.”
Lafranceschina, S., Brunetti, O., Delvecchio, A., Conticchio, M., Ammendola, M., Currò, G., Piardi, T., de’Angelis, N., Silvestris, N., & Memeo, R. (2019) · Cancers · doi:10.3390/cancers11111718 · Cited by 41
Takahashi, H., Katsuta, E., Yan, L., Tokumaru, Y., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12082033 · Cited by 45
“LVI and PNI are commonly positive in PDAC, and have been reported in as many as 50–75% and 75–100% of specimens, respectively [5,7,16,17].”
BackgroundResultParker, N. H., Gorzelitz, J., Ngo‐Huang, A., Caan, B. J., Prakash, L., Garg, N., Petzel, M. Q. B., Schadler, K., Basen‐Engquist, K., & Katz, M. H. G. (2021) · Integrative Cancer Therapies · doi:10.1177/1534735420986615 · Cited by 46
“Specifically, these patients presented (1) in 2015 prior to the opening of enrollment in the exercise study, (2) in 2015 during a several-month pause in exercise study enrollment, or (3) following the completion of exercise study enrollment in early 2017.”
BackgroundStroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects
Polani, F., Grierson, P. M., & Lim, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i18.2105 · Cited by 49
Mahajan, U. M., Li, Q., Alnatsha, A., Maas, J., Orth, M., Maier, S. H., Peterhansl, J., Regel, I., Sendler, M., Wagh, P. R., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.055 · Cited by 52
Zhao, T., Cao, K., Yao, J., Nogues, I., Lü, L., Huang, L., Xiao, J. Z., Yin, Z., & Zhang, L. (2021) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr46437.2021.01353 · Cited by 41
“Early diagnosis is crucial, as it can potentially increase the five-year survival rate to ∼ 50% [5].”
BackgroundStriefler, J. K., Riess, H. B., Lohneis, P., Bischoff, S., Kurreck, A., Modest, D. P., Bahra, M., Oettle, H., Sinn, M., Bläker, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670396 · Cited by 42
“For instance, it is unclear to which extent our findings can be generalized to cohorts using more intensive adjuvant regimens such as mFOLFIRINOX, and gemcitabine plus capecitabine (1, 2).”
BackgroundLoh, J. S., Tan, L., Lee, W.-L., Ming, L. C., How, C. W., Foo, J. B., Kifli, N., Goh, B. H., & Ong, Y. S. (2021) · Cancers · doi:10.3390/cancers13215346 · Cited by 47
Michalet, M., Bordeau, K., Cantaloube, M., Valdenaire, S., Debuire, P., Simeon, S., Portalès, F., Draghici, R., Ychou, M., Assénat, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842402 · Cited by 41
Self-citationKaramitopoulou, E., Wenning, A. S., Acharjee, A., Zlobec, I., Aeschbacher, P., Perren, A. A., & Gloor, B. (2023) · Gut · doi:10.1136/gutjnl-2022-329371 · Cited by 44
Chen, J. W., van Ramshorst, T. M. E., Lof, S., Al-Sarireh, B. A., Björnsson, B., Boggi, U., Burdı́o, F., Butturini, G., Casadei, R., Coratti, A., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-022-13054-2 · Cited by 41
Nicolle, R., Bachet, J., Harlé, A., Iovanna, J., Hammel, P. R., Rebours, V., Turpin, A., Abdelghani, M. B., Wei, A. C.-C., Mitry, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02668 · Cited by 53
Self-citationYi-ren, Y., Mou, Y., Wan, L., Zhu, S., Wang, G., Gao, H., & Liu, B. (2024) · Medicinal Research Reviews · doi:10.1002/med.22057 · Cited by 49
Kalisvaart, M., Broadhurst, D., Marcon, F., Pandé, R., Schlegel, A. A., Sutcliffe, R. P., Marudanayagam, R., Mirza, D. F., Chatzizacharias, N. A., Abradelo, M., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.01.005 · Cited by 40
Fifty Years of Surgery for Pancreatic Cancer
Hackert, T., Klaiber, U., Pausch, T. M., Mihaljević, A. L., & Büchler, M. W. (2020) · Pancreas · doi:10.1097/mpa.0000000000001634 · Cited by 40
“003).(16) Because of the increased toxicity of modified FOLFIRINOX; however, it is reserved for patients in good clinical condition.”
BackgroundNoncoding RNAs in drug-resistant pancreatic cancer: A review
Lin, Z., Lu, S. Y., Xie, X., Yi, X., & Huang, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110768 · Cited by 40
Park, H. S., Kang, B., Chon, H. J., Im, H.-S., Lee, C., Kim, I., Kang, M. J., Hwang, J.-E., Bae, W. K., Cheon, J., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100049 · Cited by 40
Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development
Bellotti, R., Speth, C., Adolph, T. E., Lass‐Flörl, C., Effenberger, M., Öfner, D., & Maglione, M. (2021) · Cancers · doi:10.3390/cancers13143431 · Cited by 42
Wang, Y., Chen, F., Zhou, H., Huang, L., Ye, J., Liu, X., Sheng, W., Gao, W., Yu, H., & Wang, F. (2022) · Small Methods · doi:10.1002/smtd.202200888 · Cited by 43
Kim, D. W., Ahn, H., Kim, K. W., Lee, S. S., Kim, H. J., Ko, Y., Park, T., & Lee, J. (2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0277 · Cited by 43
“Our results showing a significant association between adjuvant treatment and muscle type suggested that patients with impaired muscle function were less likely to receive adjuvant treatment compared to patients with normal muscle function owing to their poor postoperative health status, which may have significantly co…”
ResultSurvival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma
Topal, H., Aerts, R., Laenen, A., Collignon, A. M. F., Jaekers, J., Geers, J., & Topal, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.48147 · Cited by 41
van Eijck, C. W. F., Mustafa, D. A. M., Vadgama, D., de Miranda, N. F. C. C., Koerkamp, B. G., van Tienhoven, G., van der Burg, S. H., Malats, N., & van Eijck, C. H. J. (2023) · Gut · doi:10.1136/gutjnl-2023-330480 · Cited by 44
Gaps and Opportunities in the Diagnosis and Treatment of Pancreatic Cancer
Caban, M., & Małecka-Wojciesko, E. (2023) · Cancers · doi:10.3390/cancers15235577 · Cited by 50
“Nonetheless, more toxicity was also observed [159].”
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
Liu, J., Tian, R., Sun, C., Guo, Y., Dong, L., Li, Y., & Song, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290414 · Cited by 41
Mackay, T. M., Latenstein, A. E. J., Augustinus, S., van der Geest, L. G., Bogte, A., Bonsing, B. A., Cirkel, G. A., Hol, L., Busch, O. R., den Dulk, M., et al. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2023.7872 · Cited by 49
Fraunhoffer, N. A., Hammel, P. R., Conroy, T., Nicolle, R., Bachet, J., Harlé, A., Rebours, V., Turpin, A., Abdelghani, M. B., Mitry, E., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.010 · Cited by 51
Self-citationEmerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer
Li, Y., Wu, J., Wang, J., & Xiang, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.041 · Cited by 42
Wolfe, A. R., Prabhakar, D., Yildiz, V. O., Cloyd, J. M., Dillhoff, M. E., Abushahin, L. I., Diaz, D. A., Miller, E. D., Chen, W., Frankel, W. L., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3075 · Cited by 41
Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma
Flammang, I., Reese, M., Ströse, A., Yang, Z., Eble, J. A., & Dhayat, S. A. (2020) · Cancers · doi:10.3390/cancers12061693 · Cited by 42
“Nevertheless, response rates to chemotherapy are reported to be as low as 9.4–31.6% in the metastatic setting, yet another reason for the fatal prognosis of the disease [3–5].”
BackgroundInfluentialWeight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer
Hue, J. J., Sugumar, K., Kyasaram, R. K., Shanahan, J., Lyons, J. L., Ocuin, L. M., Rothermel, L. D., Hardacre, J. M., Ammori, J. B., Rao, G., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09861-8 · Cited by 41
“yet the same regimen provided a 19-month survival advantage for patients with localized and resected disease.(3) There are rarely any long-term survivors when macroscopic distant metastases are identified during staging evaluation.”
BackgroundJanssen, Q. P., van Dam, J. L., Kivits, I. G., Besselink, M. G., van Eijck, C. H. J., Homs, M. Y. V., Nuyttens, J. J. M. E., Qi, H., van Santvoort, H. C., Wei, A. C.-C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10276-8 · Cited by 47
Self-citationPhotodynamic Therapy for Pancreatic Ductal Adenocarcinoma
Karimnia, V., Slack, F. J., & Celli, J. P. (2021) · Cancers · doi:10.3390/cancers13174354 · Cited by 47
“In a later study, survival benefit was observed to be further enhanced using a modified FOLFIRINOX combination [10].”
MethodCarotenuto, P., Amato, F., Lampis, A., Rae, C. J., Hedayat, S., Previdi, M. C., Zito, D., Raj, M., Guzzardo, V., Sclafani, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27099-6 · Cited by 42
Ghanem, I., Lora, D., Herradón, N., de Velasco, G., Carretero-González, A., Varas, M. Á. J., de Parga, P. V., & Feliú, J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100485 · Cited by 39
de Andrés, M. P., Jackson, R., Felipe‐Abrio, I., Zagorac, S., Pilarsky, C. P., Schlitter, A. M., de Villarreal, J. M., Jang, G. H., Costello, E., Gallinger, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325803 · Cited by 40
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer
Ben‐Ami, R., Wang, Q.-L., Zhang, J., Supplee, J., Fahrmann, J. F., Lehmann‐Werman, R., Brais, L. K., Nowak, J. A., Yuan, C., Loftus, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-331074 · Cited by 83
Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC
Oba, A., Bao, Q. R., Barnett, C. C., Al-Musawi, M. H., Croce, C., Schulick, R. D., & Chiaro, M. D. (2020) · Scandinavian Journal of Surgery · doi:10.1177/1457496919900413 · Cited by 38
Yoo, C., Lee, S. S., Song, K. B., Jeong, J. H., Hyung, J., Park, D. H., Song, T. J., Seo, D. W., Lee, S. K., Kim, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0867-x · Cited by 38
Flickinger, J. C., Singh, J., Carlson, R. D., Leong, E., Baybutt, T. R., Barton, J. R., Caparosa, E. M., Pattison, A. M., Rappaport, J. A., Roh, J. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001046 · Cited by 40
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
Hilmi, M., Éderhy, S., Waintraub, X., Funck‐Brentano, C., Cohen, A. A., Vozy, A., Lebrun‐Vignes, B., Moslehi, J. J., Nguyen, L. S., & Salem, J. (2020) · Pharmaceuticals · doi:10.3390/ph13100325 · Cited by 42
“Median time to onset for HF (75 days, IQR [22,166]) was longer vs.”
BackgroundInfluentialAutophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
Gillson, J., El-Aziz, Y. S. A., Leck, L. Y. W., Jansson, P. J., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2022) · Cancers · doi:10.3390/cancers14143528 · Cited by 42
ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer
Purohit, V., Wang, L., Yang, H., Li, J., Ney, G. M., Gumkowski, E. R., Vaidya, A. J., Wang, A., Bhardwaj, A., Zhao, E., et al. (2021) · Genes & Development · doi:10.1101/gad.344184.120 · Cited by 40
“TheNRF2-Neh2domaincontainstwobindingmotifs, DLGandETGE,whichareresponsibleforKEAP1/NRF2 binding (Davies et al. 2016; Rojo de la Vega et al. 2018).”
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 45
“Abraxane inhibits the depolymerisation of microtubules to arrest mitosis and induce cancer cell death [10], while FOLFIRINOX is a cocktail of cytotoxic drugs, including fluorouracil, irinotecan and oxaliplatin as well as leucovorin, which has been proven to be effective in PDAC [7,11].”
BackgroundCirculating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer
Jaworski, J. J., Morgan, R. D., & Sivakumar, S. (2020) · Cancers · doi:10.3390/cancers12123704 · Cited by 41
“Indeed, a potential cure for PDAC involves surgical resection with adjuvant chemotherapy [7].”
BackgroundEvolving pancreatic cancer treatment: From diagnosis to healthcare management
Milella, M., Bassi, C., Boggi, U., Brunetti, O., Cavaliere, A., Crippa, S., Vita, F. D., Falconi, M., Frassineti, G. L., Giommoni, E., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103571 · Cited by 38
Lin, Q., Zheng, S., Yu, X., Chen, M., Zhou, Y., Zhou, Q., Hu, C., Gu, J., Xu, Z., Wang, L., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12399 · Cited by 37
“Meanwhile, to minimize the risk of the incorrect inclusion of patients withmetastatic disease, only patients with postoperative serum CA19–9 levels < 180 U/mL were included [24].”
BackgroundTanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 46
“Standardof-care chemotherapy is a regimen consisting of folinic acid (leucovorin), 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with both metastatic [7] and resected [8] PDAC.”
BackgroundDynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection
van Oosten, A. F., Groot, V. P., Dorland, G. A., Burkhart, R. A., Wolfgang, C. L., van Santvoort, H. C., He, J. P., Molenaar, I. Q., & Daamen, L. A. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005977 · Cited by 41
“6,20,22,30 A dynamic approach more accurately re fl ects the dynamic nature of PDAC and patient-speci fi c tumor biology.”
BackgroundAntibody drug conjugates: hitting the mark in pancreatic cancer?
Wittwer, N. L., Brown, M. P., Liapis, V., & Staudacher, A. H. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02868-x · Cited by 40
“First line-treatment regimens include the combination of fluorouracil, leu-covorin, irinotecan, and oxaliplatin (FOLFIRINOX) [4] and gemcitabine with nab-paclitaxel [5], depending on the patients ECOG performance status and co-morbidities [6–9].”
He, R., Hu, C., Yuan, Y., Li, T., Tian, Q., Huang, T., Lin, Q., Zheng, S., Chen, C., Fu, Z., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07431-4 · Cited by 41
“Within the array of combination chemotherapy regimens for pancreatic cancer, folinic acid, 5-fl uorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) ranks among the most ef fi cacious [8, 9].”
Hussung, S., Akhoundova, D., Hipp, J., Follo, M., Klar, R. F. U., Philipp, U., Scherer, F., von Bubnoff, N. C. C., Duyster, J., Boerries, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07736-x · Cited by 40
“The integration of more e cacious systemic chemotherapy regimens has improved median overall survival [11], yet responses of individual PDACs to chemotherapy are highly heterogeneous and personalization of perioperative therapy is in its infancy [12][13] [14][15][16][17][18] .”
BackgroundDhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 39
Oba, A., Wu, Y. H. A., Colborn, K. L., Karam, S. D., Meguid, C. L., Al-Musawi, M. H., Bao, Q. R., Gleisner, A., Ahrendt, S. A., Schulick, R. D., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac002 · Cited by 37
Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 45
“In contrast, in PDAC patients with resectable tumors (10–15%), adjuvant treatments with modified FOLFIRINOX (with a modification to exclude bolus doses of 5-fluorouracil) have contributed to the greatest improvements in survival [24,25].”
BackgroundWang, J., Liu, X., Ji, J., Luo, J., Zhao, Y., Zhou, X., Zheng, J., Guo, M., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863346 · Cited by 42
“Studies have shown that even administration of more intensified chemotherapy regimens, such as modified FOLFIRINOX, only results in modest improvement on the survival rates of PDAC patients (4).”
BackgroundEarly-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
Ulanja, M. B., Moody, A. E., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., & Alese, O. B. (2022) · Oncotarget · doi:10.18632/oncotarget.28242 · Cited by 48
Janssen, Q. P., van Dam, J. L., Prakash, L. R., Doppenberg, D., Crane, C. H., van Eijck, C. H. J., Ellsworth, S. G., Jarnagin, W. R., O'Reilly, E. M., Paniccia, A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7008 · Cited by 36
Self-citationNagai, M., Wright, M. J., Ding, D., Thompson, E. D., Javed, A. A., Weiss, M. J., Hruban, R. H., Yu, J., Burkhart, R. A., He, J. P., et al. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1303 · Cited by 37
Sugawara, T., Franco, S. R., Sherman, S., Torphy, R. J., Colborn, K. L., Franklin, O., Ishida, J., Grandi, S., Al-Musawi, M. H., Gleisner, A., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005925 · Cited by 49
Murakawa, M., KAWAHARA, S., Takahashi, D., Kamioka, Y., Yamamoto, N., Kobayashi, S., Ueno, M., Morimoto, M., Sawazaki, S., Tamagawa, H., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03141-3 · Cited by 47
Molecular envoys pave the way for pancreatic cancer to invade the liver
Maitra, A. (2019) · Nature · doi:10.1038/d41586-019-00710-z · Cited by 43
Matsuda, Y., Inoue, Y., Hiratsuka, M., Kawakatsu, S., Arai, T., Matsueda, K., Saiura, A., & Takazawa, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222155 · Cited by 36
Heidsma, C. M., Hyer, M., Tsilimigras, D. I., Rocha, F. G., Abbott, D. E., Fields, R. C., Smith, P. M., Poultsides, G. A., Cho, C. S., Maithel, S. K., et al. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25900 · Cited by 36
The Tumor Microenvironment of Pancreatic Cancer
Karamitopoulou, E. (2020) · Cancers · doi:10.3390/cancers12103076 · Cited by 40
Damm, M., Efremov, L., Birnbach, B., Terrero, G., Kleeff, J. H., Mikolajczyk, R., Rosendahl, J., Michl, P., & Krug, S. (2021) · Cancers · doi:10.3390/cancers13174326 · Cited by 36
“5 years in selected patient groups [4,7,8].”
Background
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.